Striking a Balance for AV Testing

# Striking a Balance for AV Testing

A balanced assay panel is essential for adenovirus vector (AV) quality control. Because AV products package both complete and empty particles, no single analytical dimension can describe product quality. This article outlines the cOre testing workflow for AV products, from sample receipt through method selection to acceptance judgment, and explains how to balance sensitivity, throughput, and turnaround.

scope & core parameters

AV testing covers process intermediates, purified bulk, and final drug product. Core parameters fall into four dimensions. Infectious titer reflects functional virus particles. Physical titer counts total particle concentration. Purity and impurity profile covers residual host-cell proteins, host-cell DNA, and process-related contaminants. Safety attributes include sterility, mycoplasma, and endotoxin. The ratio of physical particles to infectious units is a key derived indicator. An elevated ratio suggests a high proportion of empty or non-infectious capsids. Each parameter is measured by an orthogonal method set, and results are interpreted jointly rather than in isolation. The testing scope should match the product's developmental stage, from early characterization to release testing under a validated protocol.

Sample types & collection

Applicable sample types include clarified cell lysate, chromatography elution fractions, purified virus stock, formulated bulk, and finished vials. Collect samples with aseptic technique and store them frozen, typically below -60 °C for long-term hold. Avoid repeated freeze-thaw cycles, which reduce infectivity. Aliquot samples into single-use volumes to minimize titer loss from repeated handling. For sterility and mycoplasma testing, sampling must occur before any preservative is added. Each submission should include sample information: matrix composition, buffer formulation, expected titer range, biosafety level, and known cytotoxicity toward the indicator cell line. Matrix components such as salts, glycerol, or surfactants can interfere with spectrophotometric and cell-based assays. Plan dilution series during sample preparation to place measurements within the linear range of each method.

Infectious

titer assay — TCID50 & plaque assay
Infectious titer is determined on a permissive cell line, commonly a human embryonic kidney-derived line that supports adenovirus replication. Two classical formats are used. The TCID50 method inoculates serial dilutions of the sample onto cell monolayers in multi-well plates. Cytopathic effect is scored after an incubation period. The 50% tissue culture infectious dose is calculated by the Spearman-Kärber or Reed-Muench algorithm. The plaque assay overlays infected monolayers with a semi-solid medium so that each infectious event produces a localized plaque. Plaques are counted, and the titer is expressed as plaque-forming units per milliliter. Plaque assays give an absolute count but demand longer incubation and greater operator skill. TCID50 offers higher throughput and better suits routine lot release. Both methods depend on cell health, seeding density, and incubation conditions, which must be controlled within validated ranges for reproducible results.

Physical

titer & purity — A260, HPLC & ELISA
Physical particle concentration is measured separately from infectivity. Spectrophotometry at 260 nm measures the absorbance of viral DNA after capsid disruption. Conversion to particle concentration relies on the extinction coefficient of the vector genome. The reading represents total particles, infectious or not. Anion-exchange HPLC separates full capsids from empty or partially filled capsids. It yields a full-to-empty particle ratio that is central to product characterization. ELISA with antibodies against hexon or other capsid proteins quantifies total capsid antigen. It serves as a complementary physical titer method with good sensitivity in complex matrices. For purity assessment, SDS-PAGE with densitometry verifies the capsid protein composition. Residual host-cell DNA is quantified by qPCR, and residual host-cell protein by ELISA. Orthogonal use of these methods allows cross-checking of particle counts and detects empty-capsid enrichment introduced during purification.

Potency, sterility & co-test parameters

Potency testing links the vector's biological function to its intended mechanism. It typically measures transgene expression in a permissive cell line by ELISA, flow cytometry, or quantitative RT-PCR, reported relative to a qualified reference standard. Potency assays should reflect the mode of action and be stability-indicating. Safety co-tests follow standard biologics practice: sterility testing by direct inoculation or membrane filtration; mycoplasma detection by culture or nucleic acid methods; endotoxin by the limulus amebocyte lysate test; and bioburden for intermediates where applicable. Residual benzonase or other process enzymes, if used upstream, are controlled by dedicated assays. Adventitious agent testing applies to virus banks and harvest material. Together these co-tests frame the release package. Coordinate their sampling plans with titer assays so that a single thawed aliquot serves multiple analyses where feasible.

Acceptance

criteria & application scenarios
Acceptance criteria are set per product profile and developmental stage. Typical release logic requires the infectious titer to fall within a defined range around the target dose. The physical-to-infectious particle ratio must remain below a justified upper limit. Purity and residual impurity levels must meet pharmacopoeial expectations, and all safety tests must be negative or below limit. In early research use, criteria emphasize fitness for purpose and trend monitoring. In clinical supply, they become formal specifications with statistical justification. Application scenarios differ accordingly. Process development relies on HPLC full/empty ratio monitoring and rapid titer screening to guide chromatography. Stability studies track titer decline under storage conditions. Batch release combines infectious titer, purity, potency, and sterility. Striking a balance means matching method rigor to decision risk. It means avoiding both under-testing that hides quality drift and over-testing that delays delivery.